These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 28622272)
1. NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells. Shoae-Hassani A; Hamidieh AA; Behfar M; Mohseni R; Mortazavi-Tabatabaei SA; Asgharzadeh S J Immunother; 2017 Sep; 40(7):265-276. PubMed ID: 28622272 [TBL] [Abstract][Full Text] [Related]
2. Natural Killer-Derived Exosomal miR-186 Inhibits Neuroblastoma Growth and Immune Escape Mechanisms. Neviani P; Wise PM; Murtadha M; Liu CW; Wu CH; Jong AY; Seeger RC; Fabbri M Cancer Res; 2019 Mar; 79(6):1151-1164. PubMed ID: 30541743 [TBL] [Abstract][Full Text] [Related]
4. Identification of neuroblastoma cell lines with uncommon TAZ Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207 [TBL] [Abstract][Full Text] [Related]
5. Targeting and Therapy of Glioblastoma in a Mouse Model Using Exosomes Derived From Natural Killer Cells. Zhu L; Oh JM; Gangadaran P; Kalimuthu S; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC Front Immunol; 2018; 9():824. PubMed ID: 29740437 [TBL] [Abstract][Full Text] [Related]
6. Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma. Zhu L; Kalimuthu S; Gangadaran P; Oh JM; Lee HW; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC Theranostics; 2017; 7(10):2732-2745. PubMed ID: 28819459 [No Abstract] [Full Text] [Related]
7. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells. Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I Front Immunol; 2024; 15():1382931. PubMed ID: 38736882 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Foreman NK; Rill DR; Coustan-Smith E; Douglass EC; Brenner MK Br J Cancer; 1993 May; 67(5):933-8. PubMed ID: 8494726 [TBL] [Abstract][Full Text] [Related]
9. Immune surveillance properties of human NK cell-derived exosomes. Lugini L; Cecchetti S; Huber V; Luciani F; Macchia G; Spadaro F; Paris L; Abalsamo L; Colone M; Molinari A; Podo F; Rivoltini L; Ramoni C; Fais S J Immunol; 2012 Sep; 189(6):2833-42. PubMed ID: 22904309 [TBL] [Abstract][Full Text] [Related]
10. Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing. Belounis A; Ayoub M; Cordeiro P; Lemieux W; Teira P; Haddad E; Herblot S; Duval M Cancer Immunol Immunother; 2020 Sep; 69(9):1767-1779. PubMed ID: 32342128 [TBL] [Abstract][Full Text] [Related]
11. Differentiation-related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants. Gross N; Favre S; Beck D; Meyer M Int J Cancer; 1992 Aug; 52(1):85-91. PubMed ID: 1354203 [TBL] [Abstract][Full Text] [Related]
12. Ex vivo activation of CD56(+) immune cells that eradicate neuroblastoma. Rujkijyanont P; Chan WK; Eldridge PW; Lockey T; Holladay M; Rooney B; Davidoff AM; Leung W; Vong Q Cancer Res; 2013 Apr; 73(8):2608-18. PubMed ID: 23440424 [TBL] [Abstract][Full Text] [Related]
13. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions. Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187 [TBL] [Abstract][Full Text] [Related]
14. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Valteau-Couanet D; Leboulaire C; Maincent K; Tournier M; Hartmann O; Bénard J; Beaujean F; Boccaccio C; Zitvogel L; Angevin E Blood; 2002 Oct; 100(7):2554-61. PubMed ID: 12239169 [TBL] [Abstract][Full Text] [Related]
16. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545 [TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma-derived TGF-β1 modulates the chemokine receptor repertoire of human resting NK cells. Castriconi R; Dondero A; Bellora F; Moretta L; Castellano A; Locatelli F; Corrias MV; Moretta A; Bottino C J Immunol; 2013 May; 190(10):5321-8. PubMed ID: 23576682 [TBL] [Abstract][Full Text] [Related]
18. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292 [TBL] [Abstract][Full Text] [Related]